[ad_1]
It's a big week for Google wearabthe plans. After learning that he was paying $ 40 million for Fossil technology, the Alphab parent companyand announced it's obFDA Clearance for Electrocardiogram (ECG)the, the watch of study.
If you remember, the study watch is a prescription-only smart watch used for clinical research purposes. The watch captures the ECG, heart rate, electrodermic activity and inertial movements, which allows Verily to study serious diseases such as Parkinson's disease and MS.
Read it:The mystery contract of Google and Fossil must really keep its promises
Now, the FDA has given the go-ahead to the ECG, having approved it as a clbad II medical device, which corresponds to the authorization given to the ECG of the Apple Watch. An ECG monitors electrical activity in the heart and can be used to detect heart conditions such as atrial fibrillation.
"Cardiovascular monitoring has been one of Study Watch's areas of interest because heart disease remains the leading cause of death for both men and women in the United States," said the director. Verily's team in a blog post. The on-demand, single-driver ECG can support both population-based research and the clinical care of an individual. "
Although there is no sign that the study watch is becoming a mainstream device anytime soon, it is not important that the FDA eliminatesas this would theoretically allow Google to share this technology with its Wear OS partners.
Or, if the news from Fossil is somehow a clue that Google is planning its own hardware, the company could launch a smartwatch to finally compete with the Apple Watch. We do not know exactly what Google got from Fossil, bit could bIt's an integral part of the highly anticipated Pixel Watch.
If this is the case, the day before the study may be revealede test bed for health technology that could possibly be transferred to the Google mainstream smartwatch. Or at least, we can dream, right?
Hot Smartwatch Offers
Wareable can get a commission
Source link
